What Do Analysts Say About Immunomedics, Inc. (IMMU)


Immunomedics, Inc. (IMMU) will report its next earnings on Aug 08 AMC. The company reported the earnings of $-0.21/Share in the last quarter where the estimated EPS by analysts was $-0.15/share. The difference between the expected and actual EPS was $-0.06/share, which represents an Earnings surprise of -40%.

Many analysts are providing their Estimated Earnings analysis for Immunomedics, Inc. and for the current quarter 4 analysts have projected that the stock could give an Average Earnings estimate of $-0.22/share. These analysts have also projected a Low Estimate of $-0.31/share and a High Estimate of $-0.05/share.

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Immunomedics, Inc. might touch $53 high while the Average Price Target and Low price Target is $36 and $30 respectively.

The Relative Volume of the company is 0.87 and Average Volume (3 months) is 2.66 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -98.6%. While it’s Return on Investment (ROI) value is -200.9%.

While looking at the Stock’s Performance, Immunomedics, Inc. currently shows a Weekly Performance of 2.01%, where Monthly Performance is 2.69%, Quarterly performance is 62.37%, 6 Months performance is 58.23% and yearly performance percentage is 204.23%. Year to Date performance value (YTD perf) value is 53.53%. The Stock currently has a Weekly Volatility of 3.44% and Monthly Volatility of 4.67%.